Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion type Assertion NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_head.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion description "[Biglycan has been considered a good candidate for neuromuscular disease based on direct interactions with collagen VI and alpha-dystroglycan, both of which are linked with congenital muscular dystrophy (CMD).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_provenance.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion evidence source_evidence_literature NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_provenance.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion SIO_000772 18602826 NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_provenance.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion wasDerivedFrom befree-20150227 NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_provenance.
- NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_assertion wasGeneratedBy ECO_0000203 NP267571.RAQMJv_-1N75ZH-gur6b_Ul4x0e8XYu27VZBtmbPOdxh8130_provenance.